Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Therapy, Disease-modifying Therapy), By Major Markets, And Segment Forecasts, 2018 - 2023

Published: Aug, 2018 | Pages: 89 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global huntington's disease treatment market size is expected to be valued at USD 1.5 billion by 2023, as per a new report by Grand View Research, Inc., registering a CAGR of 38.2% during the forecast period. The market is largely driven by factors such as rapid uptake of disease-modifying therapies, increased adoption of novel therapeutics, and increase in R&D activities.

Huntington's disease is an inherited neurodegenerative disorder characterized by a combination of motor, cognitive, and psychiatric symptoms. Currently, only two symptom-alleviating therapies are specifically approved for this disorder: Xenazine and Austedo. Off-label medications are used extensively due to lack of approved alternatives.

The pipeline for Huntington's disease is expected to witness rapid developments in the coming years as disease-modifying drugs transform the market landscape. Improved disease understanding has led to significant progress in the development of therapeutic approaches aimed at modifying specific changes linked to the causative mutation. The potential role of RNA antisense technology and stem cell therapy are under active clinical investigation. Wave Life Sciences and Ionis Pharma's antisense oligonucleotides aim to target underlying disease cause and are expected to contribute significantly to market growth.

Further key findings from the report suggest:

• Teva is projected to become the market leader, capturing more than 45% of the market in 2023, driven by Austedo's rapid uptake and improved efficacy profile compared to its competitors. Teva's Huntexil is expected to be the only new symptom-alleviating drug to be launched during the forecast period

• Raptor's RP103 is expected to face head-to-head competition from Prana Biotech's Phase II drug PBT2 to be the first disease modifying therapy to be launched in the market

• Currently, 23 products are under clinical investigation for Huntington's disease, out of which, one is in Phase II/III each, thirteen in Phase II trials, two in Phase Ib/IIa, six in pre-clinical trials, and one in discovery phase

• EU5 will remain the second largest market with more than 15% share in 2023, driven by rising disease prevalence, novel drug launches, and increase in R&D activities

• Companies are now focusing on development of treatments that can be injected directly in the brain to directly inhibit the formation of mutant HTT protein, instead of targeting the mutant protein

• Drugs with novel targets in early-phase development include Stealth Biotherapeutics' SBT-20 (mitochondria-targeted cytoprotective peptide), Cellavita + Azidus Brazil's Cellavita HD (stem cell therapy), Sangamo/ Shire's mHTT ZFP (zinc finger protein), and UniQure's AMT-130 (gene therapy).

 Table of Contents

Chapter 1 Research Methodology
                 1.1. Information procurement
                 1.2. Information or Data Analysis
                     1.2.1. Market Formulation & Validation
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
                 3.1 Disease Primer
                     3.1.1 Molecular Biology and Genetics of Huntington Disease (HD) 
                     3.1.2 Signs and Symptoms
                     3.1.3 Biomarkers
                     3.1.4 Current Prevalence and Incidence Rate for Seven Major Markets (U.S., Japan, EU5) 
Chapter 4 Global Huntington's Disease Treatment Market Overview
                 4.1 Therapeutic Classes for HD
                 4.2 Market, by Treatment
                 4.3 Sales Performance, by Treatment (2017 - 2023) 
                     4.3.1 Symptomatic Therapy
                     4.3.2 Disease - Modifying Therapy
                 4.4 Market, by Mode of Administration
                 4.5 Market Size and Forecast (2017 - 2023) 
                 4.6 Market Size and Forecast, by Seven Major Markets (2017 - 2023) 
                     4.6.1 U.S., Sales by Treatment (2017 - 2023)
                     4.6.2 U.K., Sales by Treatment (2017 - 2023)
                     4.6.3 Germany, Sales by Treatment (2017 - 2023)
                     4.6.4 France, Sales by Treatment (2017 - 2023)
                     4.6.5 Italy, Sales by Treatment (2017 - 2023)
                     4.6.6 Spain, Sales by Treatment (2017 - 2023)
                     4.6.7 Japan, Sales by Treatment (2017 - 2023)
                 4.7 Market Share Distribution, by Company (2017 - 2023) 
                 4.8 Market Dynamics and Brand Strategies
                 4.9 Patent Expiry Analysis
                 4.10 Huntington's Disease Treatment Market: Drivers and Restraints
                     4.10.1 Market Drivers
                     4.10.2 Market Restraints
                 4.11 M&A, Deal Landscape (2013 - 2018 YTD) 
                     4.11.1 Mergers & Acquisitions
                     4.11.2 Deals Landscape
                 4.12 Pricing and Reimbursement Scenario
                 4.13 Huntington's Disease Sector SWOT
Chapter 5 Huntington's Disease Treatment Market: Pipeline Intelligence
                 5.1 Pipeline Landscape
                     5.1.1 Leading Drugs in Development
                 5.2 Key R&D Trends
                     5.2.1 Gene Therapy
                         5.2.1.1 Antisense Oligonucleotides (ASO) 
                         5.2.1.2 Gene Therapy with miRNAs
                         5.2.1.3 mRNA Splicing (Splicing Interference) 
                         5.2.1.4 Zinc - Finger DNA Binding Protein (ZFP) 
                     5.2.2 Stem Cell Therapy
                     5.2.3 Small Molecules
                 5.3 Pipeline Landscape
                     5.3.1 Late Stage Pipeline Drugs
                 5.4 Clinical Profiles of Disruptive Drugs
                 5.5 Global Pipeline Forecast
Chapter 6 Company Profiles
                 6.1 Valeant Pharmaceuticals
                     6.1.1 Company Overview
                     6.1.2 Product Portfolio - Xenazine (tetrabenazine)
                     6.1.3 Product Forecast Sales through 2023
                     6.1.4 Strategic Initiatives
                         6.1.4.1 Key Company News Flow
                     6.1.5 SWOT
                 6.2 Teva Pharmaceuticals
                     6.2.1 Company Overview
                     6.2.2 Product Portfolio - Austedo (deutetrabenazine)
                     6.2.3 Product Forecast Sales through 2023
                     6.2.4 Strategic Initiatives
                         6.2.4.1 Key Company News Flow
                     6.2.5 Pipeline Analysis and Overview
                         6.2.5.1 Catalysts and Event Calendar
                     6.2.6 SWOT
                 6.3 Ionis Pharmaceuticals
                     6.3.1 Company Overview
                     6.3.2 Product Portfolio - IONIS - HTTRx/ RG6042
                     6.3.3 Product Forecast Sales through 2023
                     6.3.4 Strategic Initiatives
                         6.3.4.1 Key Company News Flow
                         6.3.4.2 Catalysts & Events Calendar
                     6.3.5 SWOT
                 6.4 Wave Life Sciences
                     6.4.1 Company Overview
                     6.4.2 Product Portfolio - WVE - 120101 and WVE - 120102
                     6.4.3 Product Forecast Sales through 2023
                     6.4.4 Strategic Initiatives
                         6.4.4.1 Key Company News Flow
                         6.4.4.2 Catalysts & Events Calendar
                     6.4.5 SWOT
                 6.5 Horizon Pharma
                     6.5.1 Company Overview
                     6.5.2 Product Portfolio - Procysbi (RP103) 
                     6.5.3 Product Forecast Sales through 2023
                     6.5.4 Strategic Initiatives
                         6.5.4.1 Key Company News Flow
                     6.5.5 SWOT
                 6.6 Prana Biotech
                     6.6.1 Company Overview
                     6.6.2 Product Portfolio - PBT2
                     6.6.3 Product Forecast Sales through 2023
                     6.6.4 Strategic Initiatives
                         6.6.4.1 Key Company News Flow
                     6.6.5 SWOT
Chapter 7 Market Outlook
                 7.1. What the Future Holds
                 7.2. The Winners and Losers
                     7.2.1. Winners
                     7.2.2. Losers
                 7.3. Emerging Companies/New Technology Platforms
                     7.3.1. Vaccinex
                     7.3.2. UniQure
                     7.3.3. Stealth BioTherapeutics
                     7.3.4. Azevan Pharmaceuticals
                     7.3.5. Voyager Therapeutics
                     7.3.6. Sangamo/ Shire
                 7.4. The Road Ahead

List of Tables

TABLE 1 Huntington's Disease - Classification based on CAG Repeats
TABLE 2 Huntington's Disease - Prevalence
TABLE 3 Huntington's Disease - Incidence (New cases)
TABLE 4 Antidopaminergics - Drugs Specifically Approved for Huntington's disease
TABLE 5 Drugs Prescribed Off - label for Huntington's Disease
TABLE 6 Sales by Treatment Type, in $ Million, 2017 - 2023
TABLE 7 Sales Performance by Geographic Markets, in $ Million, 2017 - 2023
TABLE 8 U.S., Sales by Treatment (2017 - 2023)
TABLE 9 U.K., Sales by Treatment (2017 - 2023)
TABLE 10 Germany, Sales by Treatment (2017 - 2023)
TABLE 11 France, Sales by Treatment (2017 - 2023)
TABLE 12 Italy, Sales by Treatment (2017 - 2023)
TABLE 13 Spain, Sales by Treatment (2017 - 2023)
TABLE 14 Japan, Sales by Treatment (2017 - 2023)
TABLE 15 Patent Expiry Analysis
TABLE 16 U.S. Patents for Austedo
TABLE 17 R&D Pipeline Overview - Active Clinical Trials in Huntington's Disease
TABLE 18 Gene - Silencing Therapies Under Development for Huntington's Disease
TABLE 19 Late Stage Pipeline Analysis
TABLE 20 Nerventra (laquinimod)
TABLE 21 VX - 15
TABLE 22 Cellavita HD
TABLE 23 AMT - 130
TABLE 24 Pipeline Forecast
TABLE 25 Valeant Pharma Product Forecast Sales (2017 - 2023)
TABLE 26 Teva Pharmaceuticals Product Forecast Sales (2017 - 2023)
TABLE 27 Horizon Pharma Product Forecast Sales (2017 - 2023)
TABLE 28 Prana Biotech - Product Forecast Sales (2017 - 2023)

List of Figures

FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 U.S. - Mortality due to Huntington's disease (Rate/ 100,000)
FIG. 8 Therapy Type, Market Share Distribution, 2017 and 2023
FIG. 9 Market, by Mode of Administration, 2017 & 2023
FIG. 10 Regional Market Size, 2017 & 2023
FIG. 11 Market Shares Distribution, by Company (2017 & 2023)
FIG. 12 Huntington's Disease Therapeutic Sector SWOT
FIG. 13 Huntington's Disease R&D Pipeline - Drugs in Development
FIG. 14 Huntington's Disease R&D Pipeline, by Treatment Type
FIG. 15 Valeant Pharma HD Sales Forecast
FIG. 16 Valeant SWOT Analysis 
FIG. 17 Teva HD Sales Forecast
FIG. 18 Teva SWOT Analysis 
FIG. 19 Ionis Pharmaceuticals Sales Forecast
FIG. 20 Ionis Pharmaceuticals SWOT Analysis 
FIG. 21 Wave Life Sciences HD Sales Forecast
FIG. 22 Wave Life Sciences SWOT Analysis
FIG. 23 Horizon Pharma HD Sales Forecast
FIG. 24 Horizon Pharma SWOT Analysis 
FIG. 25 Prana Biotech HD Sales Forecast
FIG. 26 Prana Biotech SWOT Analysis